GLAND · NSE
Not in active coverage. Cited reporting has mentioned Gland Pharma, the record of those mentions is below. Your interest is logged; coverage expands by demand.
Gland Pharma will invest $21 million in its US subsidiary, which will acquire a 60% stake in newly incorporated Novelstar Pharma.
Gland Pharma's Board of Directors has approved the acquisition of 100 percent of the equity share capital of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd.
Fosun Pharma Industrial sold a 4.55 per cent stake in Gland Pharma for Rs 2,121.50 crore through block deals, reducing its holding to 47.22 per cent.
Fosun Pharma sold 98.97 lakh shares, representing approximately 6% equity, in Gland Pharma for an estimated Rs 2,800 crore through a block deal.
Gland Pharma shares fell 3% to Rs 2,827 on the BSE after 1.22 crore shares changed hands in two separate block deals worth Rs 2,941 crore and Rs 2,877 crore, with promoter Fosun Pharma Industrial reportedly looking to divest a 5% stake.
Gland Pharma shares fell on Friday, September 4, after 75 lakh shares or 4.5% equity of the company changed hands in a block deal window for around ₹2,100 crore.
Jefferies included 10 stocks as part of its bottom-up top ideas within its 261 stock coverage, including ICICI Bank, Cholamandalam, SBI Life, TVS Motor, Emmvee Photovoltaic, Hindustan Zinc, Tata Consumer, Eternal, Gland Pharma and Indian Hotels.
Gland Pharma reported consolidated net sales of Rs 1,800.27 crore in June 2026, up 19.57% year-over-year from Rs 1,505.62 crore in June 2025.
This page lists where cited reporting has mentioned Gland Pharma. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.